{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:27:22Z","timestamp":1760711242002},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"18","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Glycopyrronium, also known as glycopyrrolate, is an antimuscarinic competitive inhibitor of acetylcholine widely utilized topically for its anticholinergic properties in dermatology. A single topical glycopyrronium tosylate (GT) formulation is available on the market, and prescription of this medication has become increasingly popular among dermatologists. This medication has a relatively notable adverse effect profile and carries risks that patients need to be counseled on before initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>A 22-year-old female presented to our emergency department (ED) with a chief complaint of difficulty urinating for 48 hours and blurred vision for 2 weeks. Over the course of a week, she visited the ED once and urgent care multiple times due to complications associated with combination use of GT and cetirizine. Although these clinical effects were reversible, the patient impact in our case was profound given the time, cost, and invasive nature of these visits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The notable adverse effects of GT should be considered when prescribing this agent.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxad141","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T10:09:47Z","timestamp":1686996587000},"page":"1234-1237","source":"Crossref","is-referenced-by-count":2,"title":["Urinary retention and mydriasis secondary to topical glycopyrronium for axillary hyperhidrosis"],"prefix":"10.1093","volume":"80","author":[{"given":"Holly Hoshall","family":"Green","sequence":"first","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lance","family":"Ray","sequence":"additional","affiliation":[{"name":"Denver Health and Hospital Authority , Denver, CO"},{"name":"Department of Emergency Medicine, University of Colorado Anschutz , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennie","family":"Buchanan","sequence":"additional","affiliation":[{"name":"Denver Health and Hospital Authority , Denver, CO"},{"name":"Department of Emergency Medicine, Rocky Mountain Poison and Drug Safety , Denver, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Matsler","sequence":"additional","affiliation":[{"name":"Denver Health and Hospital Authority , Denver, CO"},{"name":"Department of Emergency Medicine, Rocky Mountain Poison and Drug Safety , Denver, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"issue":"10","key":"2023090706235519900_CIT0001","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00403-016-1697-9","article-title":"Hyperhidrosis: an update on prevalence and severity in the United States","volume":"308","author":"Doolittle","year":"2016","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"2023090706235519900_CIT0002","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13555-016-0148-z","article-title":"Current and emerging medical therapies for primary hyperhidrosis","volume":"7","author":"Grabell","year":"2017","journal-title":"Dermatol Ther"},{"issue":"12","key":"2023090706235519900_CIT0003","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1080\/15563650.2022.2132768","article-title":"2021 annual report of the National Poison Data System (NPDS) from America\u2019s Poison Centers: 39th annual report","volume":"60","author":"Gummin","year":"2022","journal-title":"Clin Toxicol"},{"key":"2023090706235519900_CIT0004","article-title":"Glycopyrrolate","volume-title":"StatPearls","author":"Gallanosa"},{"key":"2023090706235519900_CIT0005","article-title":"Anticholinergic toxicity","volume-title":"StatPearls","author":"Broderick"},{"issue":"6","key":"2023090706235519900_CIT0006","doi-asserted-by":"crossref","first-page":"e300","DOI":"10.1016\/j.jcjo.2019.04.009","article-title":"Reversible anisocoria due to inadvertent ocular exposure to topical anticholinergic treatment for primary axillary hyperhidrosis","volume":"54","author":"Pashaei-Marandi","year":"2019","journal-title":"Can J Ophthalmol"},{"issue":"1","key":"2023090706235519900_CIT0007","first-page":"187","article-title":"Dilated pupils caused by topical glycopyrrolate for hyperhidrosis","volume":"158","author":"Panting","year":"2008","journal-title":"Br J Dermatol"},{"issue":"5","key":"2023090706235519900_CIT0008","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jcjo.2020.06.009","article-title":"Pharmacologic anisocoria secondary to topical glycopyrronium for axillary hyperhidrosis: an emerging clinical presentation","volume":"55","author":"Kaufman","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"2023090706235519900_CIT0009","doi-asserted-by":"crossref","first-page":"797.e1","DOI":"10.1016\/j.ajem.2021.01.060","article-title":"A new medication, a new toxidrome\u2014a case report of anticholinergic wipe toxicity due to improper medication use","volume":"46","author":"Michael","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"4","key":"2023090706235519900_CIT0010","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/WNO.0000000000001567","article-title":"Pharmacologic mydriasis secondary to topical glycopyrronium tosylate cloths: clinical characterization from a multicenter analysis","volume":"42","author":"Kaufman","year":"2022","journal-title":"J Neuroophthalmol"},{"issue":"6","key":"2023090706235519900_CIT0011","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jaapos.2019.09.012","article-title":"Pharmacologic mydriasis in an infant following parental use of topical glycopyrronium tosylate","volume":"23","author":"Seto","year":"2019","journal-title":"J AAPOS"},{"issue":"1","key":"2023090706235519900_CIT0012","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jaapos.2021.08.301","article-title":"Anisocoria secondary to antiperspirant wipes in a pediatric population: a case series","volume":"26","author":"Pecha","year":"2022","journal-title":"J AAPOS"},{"key":"2023090706235519900_CIT0013","volume-title":"Assessment Report: Glycopyrronium Inhalation Powder","author":"Breezhaler","year":"2012"},{"key":"2023090706235519900_CIT0014","year":"2021"},{"issue":"1","key":"2023090706235519900_CIT0015","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jaad.2018.07.002","article-title":"Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials","volume":"80","author":"Glaser","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2023090706235519900_CIT0016","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40257-019-00446-6","article-title":"A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis","volume":"20","author":"Glaser","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"2023090706235519900_CIT0017","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40262-020-00975-y","article-title":"Limited systemic exposure with topical glycopyrronium tosylate in primary axillary hyperhidrosis","volume":"60","author":"Pariser","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"2023090706235519900_CIT0018","year":"2018"},{"key":"2023090706235519900_CIT0019","doi-asserted-by":"crossref","first-page":"270.e1","DOI":"10.1016\/j.ajem.2021.08.062","article-title":"Unintentional cetirizine overdose causing anticholinergic syndrome","volume":"52","author":"Renko","year":"2022","journal-title":"Am J Emerg Med"},{"issue":"5","key":"2023090706235519900_CIT0020","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1001\/archinternmed.2007.106","article-title":"The anticholinergic risk scale and anticholinergic adverse effects in older persons","volume":"168","author":"Rudolph","year":"2008","journal-title":"Arch Intern Med"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxad141\/50861195\/zxad141.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/18\/1234\/51405991\/zxad141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/18\/1234\/51405991\/zxad141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T06:26:17Z","timestamp":1694067977000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/18\/1234\/7205251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":20,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,6,22]]},"published-print":{"date-parts":[[2023,9,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxad141","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,15]]},"published":{"date-parts":[[2023,6,22]]}}}